DGAP-News

CVR Medical Announces Letter of Intent to Acquire Additional Interest

DGAP-News: CVR Medical Corp. / Key word(s): Miscellaneous CVR Medical Announces Letter of Intent to Acquire Additional Interest 09.03.2017 / 14:30 The issuer is solely responsible for the content of this announcement.

---

Vancouver, British Columbia--(Newsfile Corp. - March 9, 2017) - CVR Medical
Corp. (TSXV: CVM) (FSE: B3BN) (OTCQB: CRRVF) ('CVR Medical') is pleased to
report that it has entered into a letter of intent with CVR Global Inc.
('CVR Global') to acquire an additional 10% interest of the 'Joint Venture
Business' from CVR Global's current 50% interest (the 'Transaction'). The
Joint Venture Business is held pursuant to, and governed by, the terms of
the Joint Venture Agreement between CVR Global and CVR Medical. Upon
closing of the Transaction, the Joint Venture Business and related assets
will be transferred into a new corporate entity to be established for the
ongoing ownership and operation of the business. The purchase price for the
Transaction will be 3,000,000 common shares of CVR Medical (the
'Consideration Shares') and concurrently with the closing of the
Transaction, the parties will enter into a shareholders agreement in
regards to the new corporate entity that will assume the Joint Venture
Business.

The proposed Transaction and issuance of the Consideration Shares remain
subject to acceptance of the TSX Venture Exchange.

The securities referred to herein will not be or have not been registered
under the United States Securities Act of 1933, as amended, and may not be
offered or sold in the United States absent registration or an applicable
exemption from registration requirements.

For additional information on the organization, leadership, and current
news please visit the company website at www.CVRMed.com

About CVR Medical

CVR Medical is a company that is involved in an equal parts joint venture
with CVR Global Inc. (the 'Joint Venture'). The Joint Venture operates in
the medical industry focused on the commercialization of a proprietary
subsonic, infrasonic, and low frequency sound wave analysis technology and
has patents to a diagnostic device designed to detect and measure carotid